BINDING TO OTHER ORAL MEDICATIONS
See full prescribing information for complete boxed warning.
- TRADE NAME: Veltassa (Relypsa)
- INDICATIONS: Hyperkalemia
- CLASS: Potassium binder
- HALF-LIFE: N/A
- FDA APPROVAL DATE: 10/21/2015
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: Not expected to cause fetal risk
Please login to view the rest of this drug profile.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/20/2025
